Skip to content

Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia

Comparing the Effectiveness of High or Low Dose of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03820518
Enrollment
100
Registered
2019-01-29
Start date
2017-01-01
Completion date
2022-12-31
Last updated
2019-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X-linked Hypophosphatemia

Brief summary

X-linked hypophosphatemia (XLH) is the most common form of heritable rickets. Current treatments include active vitamin D metabolites (e.g. calcitriol) and phosphate salts. There is no consistent weight-based dosing of calcitriol and phosphate now. The primary objective of this study is to establish the efficacy of different dose of calcitriol combined with neutral phosphate in children with XLH.

Interventions

DRUGCalcitriol

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Male or female, aged 1-12 years, inclusive * Diagnosis of XLH by clinical features: serum phosphorus level \< 2.5 mg/dl; ALP?; RSS total score ≥2; bowed legs; short stature; family history with appropriate X-linked inheritance * Meet at least one of the following: confirmed Phosphate regulating gene with homology to endopeptidases located on the X chromosome (PHEX) mutation in the participant, or serum FGF23 level \>30 pg/ml (Kainos assay) * Willing to participate the study, and provide an informed consent * Able to complete all aspects of study and adhere to the visit schedule

Exclusion criteria

* Use of growth hormone within 12 months before first visit * Height \>50 percentile for age and sex specific data * Presence of nephrocalcinosis or nephrolithiasis * Serum intact parathyroid hormone level\>170 pg/ml * Plan to receive orthopaedic surgery in 12 months * Poor compliance * Use of gonadotropin-releasing hormone therapy right now * Use of aluminium hydroxide, steroid, acetazolamide or thiazide drugs within 7 days before first visit * Not be fit to participant in the study, by the judgement of investigators

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline to Post-treatment in Severity of Rickets as Measured by Rickets Severity Score (RSS) Total ScoreBaseline, Month 12, 24RSS range from 0 to 10, and higher RSS represent severer rickets. It is consisted of score of worst wrist (0-4) and worst knee (0-6). WRIST-score both radius and ulna separately-2 bones × 2 points = 4 points possible KNEE-score both femur and tibia separately Multiply the grade in A by the multiplier in B for each bone, then add femur and tibia scores together A: Grade 1 2 3 B: Multiplier Portion of growth plate affected 0.5 ≤ 1 condyle or plateau 1. 2 condyles or plateaus 2. bones × 1 point × 3 points = 6 points possible Total: 10 points possible Reference:Thacher, T. Radiographic scoring method for the assessment of the severity of nutritional rickets\[J\]. Journal of Tropical Pediatrics, 2000, 46(3):132-139.

Secondary

MeasureTime frameDescription
Changes From Baseline to Post-treatment in Growth VelocityBaseline, Month 12, 24Changes From Baseline to Post-treatment in Severity of Rickets as Measured by RSS Wrist and Knee Score
Changes From Baseline to Post-treatment in Serum Total Alkaline Phosphatase (TALP) LevelsBaseline, Month 3, 6, 12, 18, 24Changes From Baseline to Post-treatment in serum ALP
Changes From Baseline to Post-treatment in serum Carboxy-terminal Collagen Crosslinks (CTX) LevelsBaseline, Month 3, 6, 12, 18, 24Changes From Baseline to Post-treatment in serum CTX
Changes From Baseline to Post-treatment in Serum Phosphorus LevelsBaseline, Month 3, 6, 12, 18, 24Changes From Baseline to Post-treatment in Serum Phosphorus Levels
Changes From Baseline to Post-treatment in Severity of Dental AbscessBaseline, Month 3, 6, 12, 18, 24The frequency and number of dental abscess will be collected by self-report and examed by investigators
Changes From Baseline to Post-treatment in Severity of Rickets as Measured by RSS Wrist and Knee ScoreBaseline, Month 12, 24RSS range from 0 to 10, and higher RSS represent severer rickets. It is consisted of score of worst wrist (0-4) and worst knee (0-6). WRIST-score both radius and ulna separately-2 bones × 2 points = 4 points possible KNEE-score both femur and tibia separately Multiply the grade in A by the multiplier in B for each bone, then add femur and tibia scores together A: Grade 1 2 3 B: Multiplier Portion of growth plate affected 0.5 ≤ 1 condyle or plateau 1. 2 condyles or plateaus 2. bones × 1 point × 3 points = 6 points possible Total: 10 points possible Reference:Thacher, T. Radiographic scoring method for the assessment of the severity of nutritional rickets\[J\]. Journal of Tropical Pediatrics, 2000, 46(3):132-139.
Changes From Baseline to Post-treatment in Severity of Leg DeformitiesBaseline, Month 3, 6, 12, 18, 24The longest distance between two sides of thighs, knees, shanks and ankles are measured to evaluate the severity of leg deformities.
Changes From Baseline to Post-treatment in Serum Osteocalcin LevelsBaseline, Month 3, 6, 12, 18, 24Changes From Baseline to Post-treatment in Serum Osteocalcin Levels
Changes From Baseline to Post-treatment in HeightBaseline, Month 3, 6, 12, 18, 24Changes From Baseline to Post-treatment in Height
Changes From Baseline to Post-treatment in Quality of Life as Measured by Patient-reported Outcomes Measurement Information SystemBaseline, Month 3, 6, 12, 18, 24Changes From Baseline to Post-treatment in Quality of Life as Measured by Patient-reported Outcomes Measurement Information System
Changes From Baseline to Post-treatment in Severity of Bone Pain as Measured by Visual Analog Pain ScalesBaseline, Month 3, 6, 12, 18, 24Visual Analog Pain Scales (VAS) range from 0-10, and higher score represents severer pain

Countries

China

Contacts

Primary ContactWeibo Xia, MD
xiaweibo8301@163.com+86 13501002126

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026